You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 12, 2025

Claims for Patent: 7,612,176

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,612,176

Title:	Polymer-based sustained release device
Abstract:	This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
Inventor(s):	Wright; Steven G. (Madeira, OH), Christensen; Troy (Mason, OH), Yeoh; Thean (Foxboro, MA), Rickey; Michael E. (Loveland, OH), Hotz; Joyce M. (Cincinnati, OH), Kumar; Rajesh (Marlborough, MA), Costantino; Henry R. (Woodinville, WA)
Assignee:	Alkermes, Inc. (Cambridge, MA)
Application Number:	11/826,535
Patent Claims:	1. A composition for sustained release of a polypeptide, consisting essentially of: a biocompatible polymer having the polypeptide dispersed therein so as to be present at about 3% (w/w) to about 5% (w/w) of the weight of the composition, and a sugar dispersed therein so as to be present at about 2% (w/w) of the weight of the composition, wherein the composition is free from additional ingredients that alter the rate of release of the polypeptide from the composition. 2. The sustained release composition of claim 1, wherein the biocompatible polymer is selected from poly(lactides), poly(glycolides), poly(lactide-co-glycolides), poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, and blends and copolymers thereof. 3. The sustained release composition of claim 2, wherein the biocompatible polymer is poly(lactide-co-glycolide) with a lactide:glycolide ratio of about 1:1. 4. The sustained release composition of claim 1, wherein the polypeptide is present at about 5% (w/w) of the weight of the composition. 5. The sustained release composition of claim 3, wherein the polypeptide is present at about 5% (w/w) of the weight of the composition. 6. The sustained release composition of claim 1, wherein the sugar is selected from a monosaccharide, a disaccharide, a sugar alcohol, and combinations thereof. 7. The sustained release composition of claim 6, wherein the sugar is selected from sucrose, mannitol, and a combination thereof. 8. The sustained release composition of claim 7, wherein the sugar is sucrose. 9. The sustained release composition of claim 1, wherein the polypeptide is present at about 5% (w/w) of the weight of the composition, and the sugar is sucrose. 10. The sustained release composition of claim 1, wherein the polypeptide is selected from a glucoregulatory peptide and pharmaceutically acceptable salts thereof. 11. The sustained release composition of claim 10, wherein the glucoregulatory peptide is selected from glucagon, glucagon-like peptides, exendins, agonists of glucagon-like peptides, vasoactive intestinal peptide, insulin, and growth hormone. 12. The sustained release composition of claim 11, wherein the glucoregulatory peptide is selected from GLP-1, GLP-2, exendin-3, exendin-4, and combinations thereof. 13. The sustained release composition of claim 12, wherein the biocompatible polymer is poly(lactide-co-glycolide) with a lactide:glycolide ratio of about 1:1. 14. The sustained release composition of claim 12, wherein the sugar is sucrose. 15. The sustained release composition of claim 12, wherein the glucoregulatory peptide is selected from exendin-3 and exendin-4. 16. A method of treating a patient having Type 2 diabetes, the method comprising: administering a therapeutically effective amount of a sustained release composition consisting essentially of a biocompatible polymer having a glucoregulatory peptide dispersed therein so as to be present at about 3% (w/w) to about 5% (w/w) of the weight of the composition, and a sugar dispersed therein so as to be present at about 2% (w/w) of the weight of the composition, wherein the composition is free from additional ingredients that alter the rate of release of the glucoregulatory peptide from the composition. 17. The method of claim 16, wherein the biocompatible polymer is poly(lactide-co-glycolide) with a lactide:glycolide ratio of about 1:1. 18. The method of claim 16, wherein the glucoregulatory peptide is present at about 5% (w/w) of the weight of the composition. 19. The method of claim 16, wherein the sugar is selected from a monosaccharide, a disaccharide, a sugar alcohol, and combinations thereof. 20. The method of claim 16, wherein the biocompatible polymer is poly(lactide-co-glycolide) with a lactide:glycolide ratio of about 1:1, wherein the glucoregulatory peptide is present at about 5% (w/w) of the weight of the composition, and the sugar is sucrose. 21. The method of claim 20, wherein the sustained release composition is administered by injection.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.